Chen et al. developed a method to predict cancer patient response to MDM2 agonists (formulas I–III) by measuring mRNA expression of MDM2, along with a panel of genes such as CDKN2A, XPC, and BBC3 [315]. Here, BBC3 is linked to cancer.